Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients
Public ClinicalTrials.gov record NCT01533922. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-blind, 5 Treatment Arms, 4-period, Incomplete Cross-over Study to Determine the Effect of 6 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (FDC) (2.5 / 5 µg; and 5 / 5 µg) (Delivered by the Respimat® Inhaler) Compared With Tiotropium (5 µg), Olodaterol (5 µg ) and Placebo (Delivered by the Respimat® Inhaler) on Lung Hyperinflation and Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease (COPD) [MORACTO TM 1]
Study identification
- NCT ID
- NCT01533922
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 295 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Tiotropium Drug
- Olodaterol Drug
- Tiotropium + Olodaterol Drug
- Respimat Device
Drug · Device
Eligibility (public fields only)
- Age range
- 40 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2012
- Primary completion
- Oct 31, 2013
- Completion
- Oct 31, 2013
- Last update posted
- Sep 14, 2015
2012 – 2013
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1237.13.01302 Boehringer Ingelheim Investigational Site | Torrance | California | — | — |
| 1237.13.01308 Boehringer Ingelheim Investigational Site | Hartford | Connecticut | — | — |
| 1237.13.01304 Boehringer Ingelheim Investigational Site | Livonia | Michigan | — | — |
| 1237.13.01307 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 1237.13.01305 Boehringer Ingelheim Investigational Site | Easley | South Carolina | — | — |
| 1237.13.01301 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1237.13.01303 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1237.13.01306 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01533922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 14, 2015 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01533922 live on ClinicalTrials.gov.